679 Results for "

availability

" in MedChemExpress (MCE) Product Catalog:
Products (679)

679 Results for "availability" in MCE Product Catalog:

22
22 Cited Publications
Referencia número: HY-12727
No. CAS: 1616391-65-1
Pureza:  99.52%
Synonyms: GSK3235025
Áreas de investigación:  

Cancer

EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 with an IC50 of 22 nM.
loading...
    loading...
20
20 Cited Publications
Referencia número: HY-A0119
No. CAS: 13755-38-9
Synonyms: Sodium nitroprusside dihydrate; Sodium Nitroferricyanide(III) Dihydrate
Target:  

Autophagy

Áreas de investigación:  

Cardiovascular Disease Cancer

Nitroprusside disodium dehydrate (Sodium nitroprusside dihydrate) is a vasodilator that available for the research of acute hypertension, heart failure. Nitroprusside disodium dehydrate induces autophagy in glutathione-depleted osteoblasts. Nitroprusside disodium dehydrate acts as a nitric oxide (NO) donor in a rat intestinal ischemia reperfusion model .
loading...
    loading...
19
19 Cited Publications
Referencia número: HY-103020
No. CAS: 1891087-61-8
Pureza:  99.73%
Target:  

Ser/Thr Kinase

Áreas de investigación:  

Cancer

BAY-1816032, a chemical probe, is a potent and oral available BUB1 (budding uninhibited by benzimidazoles 1) kinase inhibitor with an IC50 of 7 nM.
loading...
    loading...
19
19 Cited Publications
Referencia número: HY-19822
No. CAS: 722533-56-4
Synonyms: RAD1901
Target:  

Estrogen Receptor/ERR

Áreas de investigación:  

Cancer

Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER + breast cancer cell lines in vitro and in vivo .
loading...
    loading...
19
19 Cited Publications
Referencia número: HY-19822A
No. CAS: 1349723-93-8
Synonyms: RAD1901 dihydrochloride
Target:  

Estrogen Receptor/ERR

Áreas de investigación:  

Cancer

Elacestrant (RAD1901) dihydrochloride is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant dihydrochloride also can inhibit growth of ER + breast cancer cell lines in vitro and in vivo .
loading...
    loading...
19
19 Cited Publications
Referencia número: HY-13038A
No. CAS: 901119-35-5
Pureza:  99.70%
Synonyms: R788
Target:  

Syk FLT3

Áreas de investigación:  

Inflammation/Immunology Cancer

Fostamatinib (R788) is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
19
19 Cited Publications
Referencia número: HY-13038
No. CAS: 1025687-58-4
Pureza:  99.88%
Synonyms: R788Disodium
Target:  

Syk FLT3

Áreas de investigación:  

Inflammation/Immunology Cancer

Fostamatinib Disodium (R788 Disodium) is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
19
19 Cited Publications
Referencia número: HY-13038B
No. CAS: 914295-16-2
Pureza:  99.51%
Synonyms: R788 disodium hexahydrate
Target:  

Syk FLT3

Áreas de investigación:  

Inflammation/Immunology Cancer

Fostamatinib (R788) disodium hexahydrate is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
16
16 Cited Publications
Referencia número: HY-14691
No. CAS: 923032-37-5
Pureza:  99.82%
Synonyms: BAY 869766; RDEA119
Target:  

MEK

Áreas de investigación:  

Cancer

Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric MEK1/MEK2 inhibitor with IC50s of 19 nM and 47 nM, respectively.
loading...
    loading...
15
15 Cited Publications
Referencia número: HY-17359
No. CAS: 201530-41-8
Synonyms: ICL 670
Target:  

Bacterial Ferroptosis

Áreas de investigación:  

Cancer

Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
loading...
    loading...
15
15 Cited Publications
Referencia número: HY-15291
No. CAS: 1037792-44-1
Pureza:  99.68%
Target:  

GPR119

Áreas de investigación:  

Metabolic Disease

MBX-2982 is a selective, orally-available G protein-coupled receptor 119 (GPR119) agonist.
loading...
    loading...
14
14 Cited Publications
Referencia número: HY-13049
No. CAS: 857036-77-2
Pureza:  99.95%
Synonyms: AZD-2171 maleate
Target:  

VEGFR Autophagy PDGFR

Áreas de investigación:  

Cancer

Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
loading...
    loading...
14
14 Cited Publications
Referencia número: HY-10205
No. CAS: 288383-20-0
Pureza:  99.87%
Synonyms: AZD2171
Cediranib (AZD2171) is a highly potent, orally available and blood-brain barrier permeability VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
loading...
    loading...
14
14 Cited Publications
Referencia número: HY-10472
No. CAS: 1194044-20-6
Pureza:  99.62%
Target:  

Beta-secretase

Áreas de investigación:  

Neurological Disease

LY2811376 is the first orally available non-peptidic β-secretase (BACE1) inhibitor with IC50 of 239 nM-249 nM, that acts to decrease Aβ secretion with EC50 of 300 nM, and demonstrates to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin.
loading...
    loading...
13
13 Cited Publications
Referencia número: HY-12507
No. CAS: 1253186-56-9
Pureza:  99.83%
Target:  

Calcium Channel

Áreas de investigación:  

Inflammation/Immunology

GSK-7975A is a potent and orally available CRAC channel inhibitor.
loading...
    loading...
13
13 Cited Publications
Referencia número: HY-14985
No. CAS: 648903-57-5
Pureza:  99.91%
Target:  

Syk Apoptosis

Áreas de investigación:  

Inflammation/Immunology Cancer

BAY 61-3606 dihydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM an IC50 of 10 nM . BAY 61-3606 dihydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell . BAY 61-3606 dihydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates . Bay 61-3606 dihydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells .
loading...
    loading...
12
12 Cited Publications
Referencia número: HY-100493
No. CAS: 1334493-07-0
Pureza:  99.52%
Target:  

STAT

Áreas de investigación:  

Cancer

BP-1-102 is an orally available, small-molecule inhibitor of transcription factor Stat3, with an IC50 of 6.8 μM.
loading...
    loading...
12
12 Cited Publications
Referencia número: HY-K1004

MCE SYBR Green I Nucleic Acid Gel Stain is one of the most sensitive stains available for detecting double-stranded DNA (dsDNA) in agarose and polyacrylamide gels.

loading...
    loading...
12
12 Cited Publications
Referencia número: HY-120394
No. CAS: 1533438-83-3
Pureza:  99.69%
Áreas de investigación:  

Cancer

TVB-3166 is an orally-available, reversible, and selective fatty acid synthase (FASN) inhibitor with IC50s of 42 nM and 81 nM for biochemical FASN and cellular palmitate synthesis, respectively. TVB-3166 induces apoptosis, and inhibits in-vivo xenograft tumor growth .
loading...
    loading...
12
12 Cited Publications
Referencia número: HY-13007
No. CAS: 898044-15-0
Pureza:  99.79%
Synonyms: PF-03758309
Target:  

PAK Apoptosis

Áreas de investigación:  

Cancer

PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
loading...
    loading...